更高效剂量的Wegovy注射液获欧盟委员会批准

21世纪经济报道
Yesterday

21世纪经济报道记者韩利明  2月27日消息显示,欧盟委员会已批准Wegovy®(司美格鲁肽注射液)新的7.2 mg每周一次维持剂量,用于成人肥胖症患者。这一批准为医生提供了新的治疗选择,以帮助使用2.4 mg剂量后仍需更多减重的成人患者。此项批准决定基于欧洲药品管理局人用药品委员会(CHMP)于2025年12月12日发布的积极审评意见。  此次批准意味着,欧盟医生现可以开具7.2 mg剂量的处方...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10